MS-377, a novel selective σ1 receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain

European Journal of Pharmacology

Volumn 427, Issue 3, 2001, Pages 211-219

  Takahashi, Shinji ^a   Horikomi, Kazutoshi ^a   Kato, Takeshi ^b  

^a Drug Discovery Institute   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

1 Receptor ligand; Microdialysis, in vivo; MS 377; Phencyclidine; Prefrontal cortex, medial

Indexed keywords

1 (4 CHLOROPHENYL) 3 [4 (2 METHOXYETHYL)PIPERAZIN 1 YL]METHYL 2 PYRROLIDINONE TARTRATE; CLOZAPINE; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHENCYCLIDINE; SEROTONIN; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SELECTIVITY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE;

ANIMALS; BRAIN; CORPUS STRIATUM; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PIPERAZINES; PREFRONTAL CORTEX; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SEROTONIN; TARTRATES; TIME FACTORS;

EID: 0035929139     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01254-7     Document Type: Article

References (62)

1. Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via σ receptors
2. 1-adrenoceptors in the modulation of 5-HT release - III. Clozapine and the novel putative antipsychotic S 16924
3. 125I]iodosulpiride
4. 4 antagonist PNU-101387G: In vivo effects on mesocortical, mesolimbic and nigrostriatal dopamine and serotonin release
5. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
6. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia
7. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex
8. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism
9. 3H-catecholamines by rat striatal and hypothalamic synaptosomes
10. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin subtype selective antagonists in mice
11. Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism
12. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat
13. Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat
14. Neuroendocrinological and neurochemical effects of sigma ligands
15. Phencyclidine and σ opiate receptors in brain: Biochemical and autoradiographical differentiation
16. 2+ concentration
17. Effect of phencyclidine on dopamine release in the rat prefrontal cortex: An in vivo microdialysis study
18. Effects of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens
19. Recent advances in the phencyclidine model of schizophrenia
20. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats
21. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: Involvement in frontostriatal cognitive deficits
22. Clozapine for treatment-resistant schizophrenic
23. 3H]MS-377, a novel σ receptor ligand, to rat brain membranes
24. NPC 16377, a potent and selective σ-ligand: I. Receptor binding, neurochemical and neuroendocrine profile
25. In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats
26. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain
27. Effects of the serotonin2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex
28. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
29. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
30. Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats
31. Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum
32. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens
33. 2A sites for PCP-induced locomotion in the rat
34. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdialysis study
35. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys
36. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
37. NE-100, a novel sigma receptor ligand: In vivo tests
38. Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A
39. Classification and nomenclature of phencyclidine and sigma receptor sites
40. 1A receptor activation
41. 2A receptor antagonist MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat
42. 3H]serotonin uptake in synaptosomal preparations from rat brain
43. Guinea pig vas deferens contains sigma but not phencyclidine receptors
44. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors
45. Membrane binding property of a novel antipsychotic agent MS-377 in guinea pig brain
46. 1 receptors in methamphetamine-induced behavioral sensitization in rats
47. 1-ligand, MS-377, on phencyclidine-induced behaviour
48. Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat
49. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alteration performance in rats: Modulation by dopamine
50. Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: An in vivo microdialysis study
51. Implications of normal brain development for the pathogenesis of schizophrenia
52. Cortical maldevelopment, antipsychotic drugs and schizophrenia: A search for a common ground
53. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats
54. Effect of σ-1 ligand, MS-377 on apomorphine or phencyclidine-induced disruption of prepulse inhibition of acoustic startle in rat
55. Role of dopaminergic and GABAergic mechanisms in discrete brain areas in phencyclidine-induced locomotor stimulation and turning behavior
56. 3H]TCP binding to intact primary cultured neuronal cells
57. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding
58. Sigma-1 receptor ligands are preferentially uptaken into the neuronal cells compared to glial cells
59. 2 receptor
60. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex
61. 3H]cyclazocine binding to multiple receptor sites